Skip to content

Opus Genetics IRD Change in AP

Change in AP at other companies

AbbVie logo
AbbVieABBV
-$1.59B-129%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$7.91M+358%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$3.53M+1,603%
Opko Health logo
Opko HealthOPK
$3.5M-69.5%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
-$733K-128%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$107.7M+150%

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$307.14M+442%
Enterprise value$248.38M
P/S25.6×+21.5×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×
Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opus Genetics's change in AP?
Opus Genetics (IRD) reported change in AP of $1.16M in Q1 2026.
How has Opus Genetics's change in AP changed year-over-year?
Opus Genetics's change in AP increased by 260.9% year-over-year, from -$718K to $1.16M.
What is the long-term trend for Opus Genetics's change in AP?
Over 2 years (2022 to 2025), Opus Genetics's change in AP has grown at a -88.3% compound annual growth rate (CAGR), from -$515K to $7K.
What does change in AP mean?
Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.